To overcome the major disadvantages of cysteamine, the only registered treatment for the rare genetic disease cystinosis, nine prodrugs of γ-glutamyl-cysteamine (4) were synthesized for evaluation. Esterification of the thiol conferred oxidative stability, while sufficient lipophilicity for oral bioavailability was achieved by acylation of the α-carboxyl group of γ-glutamyl-cysteamine (4). Low cytotoxicity was observed in cultured HaCaT keratinocytes using the MTT assay, with
3 bioavailability, the release of strong smelling metabolites, and the gastric disturbance issues are not significantly addressed [9] . Additionally, a cysteamine concentration effect on cell viability and cell proliferation was observed in several cell lines, including cultured human fibroblasts, and excessively high doses of cysteamine have been linked to the appearance of bruise-like lesions on a number of cystinotic patients [10] .
Cysteamine is also of interest for its potential in treating other diseases, such as Huntington's disease [11, 12] , cystic fibrosis [13] [14] [15] , chronic kidney disease [16] , and non-alcoholic fatty liver disease (NAFLD), including non-alcoholic steatohepatitis (NASH) [17] . A current clinical trial is evaluating the potential of Procysbi ® as a disease-modifying treatment for
Huntington's disease. If the scope of cysteamine as a treatment increases to include these other diseases, similar compliance problems due to its side effects are likely and alternative delivery approaches therefore have wider potential application than to cystinosis alone.
Cysteamine exerts its therapeutic effect due to its ability to undergo a thiol exchange with cystine, resulting in the formation of cysteine and a cysteine-cysteamine mixed disulfide [18] (Scheme 1), which can efflux the lysosome via the transport protein PQLC2. Evidence for the involvement of this transporter in the cysteamine-driven depletion of cystine was obtained by its genetic inactivation or silencing [19, 20] . Molecular modeling has shown the structural and electronic similarities of the L-cysteine-cysteamine mixed disulfide to L-lysine, facilitating its use of this transporter [21] . initial work demonstrated the feasibility of amino acid-cysteamine conjugates as prodrugs, the depletion of cystine providing evidence of their delivery of cysteamine to cystinotic cells, with a delayed response consistent with the requirement for hydrolysis of the amino acid-cysteamine amide bond to release the active agent cysteamine [21] . A major drawback to these simple amino acid-cysteamine derivatives was their lack of clinical relevance; in particular, the thiol group confers nucleophilic and reducing properties, with disulfide bond forming potential, while α-amino acid prodrugs are known to be readily hydrolyzed in the blood [22] , which would release cysteamine and fail to prevent its metabolism. However, the initial studies also showed good depletion of accumulated cystine in cystinotic cells by γ-glutamyl-cysteamine, providing evidence of hydrolysis of the γ-glutamyl amide bond and release of cysteamine, while the α-glutamylcysteamine analogue performed poorly in comparison [21] . Initial viability experiments using γ-glutamyl-cysteamine in cells with a high expression of γ-glutamyl transpeptidase (GGT), an external cell surface enzyme that recognises and hydrolyses γ-glutamyl-derivatives, indicated low cytotoxicity [21] , providing encouragement for the further development of γ-glutamyl-cysteamine into a clinical candidate.
Prodrug design and rationale
Two further groups that are capable of bioactivation were required to convert γ-glutamylcysteamine into a candidate for clinical use: acylation of the thiol group to confer oxidative stability and an α-carboxyl ester to address the likely limitation to oral bioavailability caused by the zwitterionic nature of γ-glutamyl-cysteamine 4 ( Figure 1 ). These modifications resulted in Sthioester and α-carboxyl ester γ-glutamyl-cysteamine derivatives 1a-c, 2a-c, and 3a-c ( Figure 1 ). There are three distinct enzyme cleavage steps to release cysteamine from the prodrugs (Scheme 2), presenting two main ways to deliver the active agent cysteamine into cells after absorption from the GI tract. Firstly, satisfactory lipophilicity of the prodrugs permits rapid uptake into cells directly from the blood. Once inside the cells, the prodrugs are hydrolysed to release cysteamine, by thio/esterase activity and hydrolysis of the γ-glutamyl bond, probably by γ-glutamyl cyclotransferase. Alternatively, after uptake from the GI tract into the hepatic portal vein, the prodrugs undergo rapid esterase hydrolysis of the α-carboxyl ester (R 1 ) and thioester (R 2 ) groups in the blood and/or liver to release the key intermediate 4, targeted to γ-glutamyl transpeptidase (GGT) on the surface of cells. Interaction of γ-glutamyl-cysteamine 4 with membrane-bound GGT results in the hydrolysis of γ-glutamyl-cysteamine 4 and local release of cysteamine on the surface of the cell, allowing its rapid internalisation. Our previous studies provide evidence for the success of this approach: incubation of cystinotic cells in medium containing γ-glutamyl-cysteamine 4 resulted in significant depletion of cystine [21] .
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Scheme 2: Sequential enzymatic hydrolysis of γ-glutamyl-cysteamine prodrugs 1-3a-c to release cysteamine.
Although a low level of serum GGT is normal in humans and is increased in various disease states, such as alcoholic liver disease, the normal activity of serum GGT is around 30 times lower than that of membrane-bound GGT [26] and is likely to make only a small contribution to the release of cysteamine in the circulation. The greater resistance of γ-glutamyl amide derivatives than their α-amide isomers to proteolytic degradation by serum proteases, due to low levels of serum γ-glutamyl hydrolysis [27] , minimizes premature proteolysis of the γ-glutamyl-cysteamine bond in serum.
GGT is known to recognize a variety of small molecules linked to glutamate via an amide bond at the γ-carboxyl group [28, 29] . It is expressed on the surface of many cells across various tissues, including the proximal convoluted tubule cells of the kidney [30] , the intestinal epithelium [31] , and the luminal surface of the blood brain barrier [32] ; the accumulation of cystine appears to providing an appropriate multi-systemic treatment for cystinosis. Targeted delivery and GGTmediated release of cysteamine on the surface of cells is expected to result in its rapid uptake into cells in the near vicinity, reducing the amount of free cysteamine released into the circulation and minimizing the opportunity for liver metabolism of cysteamine, maximizing its bioavailability.
Benefits would include a less frequent and reduced therapeutic dose, minimizing issues associated with high peak serum cysteamine concentration, including the production of noxious smelling metabolites.
The success of a similar GGT-targeting strategy for the delivery of a cytotoxic glutathione analogue to pancreatic tumours was recently demonstrated [26] . The low serum activity of GGT normally observed in humans resulted in only minimal activation of the antitumour agent systemically. Targeted delivery was also achieved to the kidney with N-acyl-γ-glutamyl prodrugs of sulfamethoxazole [33] and administration of the double prodrug γ-glutamyl-L-DOPA resulted in a five-fold greater accumulation of renal dopamine than the corresponding dose of the single prodrug L-DOPA [34] .
We present here our studies on nine S-and O-diacylated γ-glutamyl-cysteamine prodrugs -their synthesis and the in vitro evaluation of their cytotoxicity, lipophilicity, cellular uptake and hydrolysis to release cysteamine.
Results

Prodrug synthesis
The synthesis of esterified prodrugs 1a-c, 2a-c and 3a-c was achieved by solution phase peptide coupling (Scheme 3).
α-Esterification of commercially sourced benzyl ester 5 with the appropriate alkyl bromide under mildly basic conditions gave esters 6a-c in good yield. Palladium-catalyzed reductive deprotection yielded the γ-carboxylic acids 7a-c, which were coupled with cysteamine using diisopropylcarbodiimide (DIC) and 1-hydroxybenzotriazole (HOBt) to give γ-glutamyl-cysteamine derivatives 8a-c. Thioesters 9a-c were formed using acetic anhydride and triethylamine, while thioesters 10a-c and 11a-c were prepared using benzoyl chloride or pivaloyl chloride, as appropriate, and pyridine.
t-Boc deprotection of compounds 9-11 using hydrochloric acid (2M) in diethyl ether gave the nine target esterified prodrugs 1a-c, 2a-c and 3a-c, respectively.
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Cytotoxicity Studies
Despite its limitations, the MTT assay allows early identification of cytotoxic or other adverse cellular effects. Initial cytotoxicity studies on esterified prodrugs 1a-c, 2a-c and 3a-c, compared to cysteamine hydrochloride, were carried out using spontaneously transformed keratinocytes from histologically normal skin (HaCaT) using a standard MTT assay, in which yellow MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) is reduced to purple formazan in metabolically active cells [35] . Percentage survival value at each concentration was derived from the data of 12 replicates, which were averaged and normalised to calculate the percentage survival. In this work, the results of the in vitro tests are expressed as EC 50 , which represents the mean dose required to kill half of the members of a test in vitro population. The EC 50
values (calculated using GraphPad Prism ® ) for γ-glutamyl-cysteamine prodrugs and cysteamine hydrochloride (Table 1) represent the dose required to kill 50% of the cells. The range of EC 50 values across the prodrugs underlines the importance of the correct choice of thioester and ester groups. In each thioester series, the ethyl esters (1a, 2a and 3a) showed lower cytotoxicity than their propyl and butyl analogues. It is unlikely that these differences are caused by differential uptake of the prodrugs due to the lipophilicity of the ester groups, as the efficient uptake of all members of the 1 st series (1a, 1b and 1c) was confirmed in subsequent experiments, when the intracellular cysteamine levels achieved by ethyl ester 1a were comparable to those achieved by propyl ester 1b and butyl ester 1c (Figure 2 ). The relatively low cytotoxicity of acetyl thioester prodrugs 1a-c and ethyl esters 2a and 3a led to selection of these prodrugs for progression to further studies designed to evaluate the uptake of these ester/thioester prodrugs of γ-glutamyl-cysteamine 4 into cultured cell lines and their subsequent intracellular hydrolysis to release cysteamine. Ethyl ester prodrug 3a was included for testing, even though it showed greater cytotoxicity than cysteamine hydrochloride, to provide an example from each series.
Physicochemical properties of esterified prodrugs
The oral bioavailability of pharmaceuticals is heavily influenced by the balance of aqueous solubility and lipophilicity, which are affected by the pK a of any ionisable groups and the consequent log P of the molecule at physiological pH values. Early investigation of these properties is therefore desirable.
Experimentally measured pK a and log P values (MlogP) were obtained using a Sirius T3 and compared with the calculated log P values (ClogP; ChemDraw The measured pK a values indicate that the prodrugs are likely to remain largely ionized throughout the GI tract after oral administration, with up to 20 % unionized amine present in the small intestine to facilitate absorption. Both the measured and calculated log P values increased in parallel with homologation of the α-ester and variation of the thioester group. Although not optimal, these characteristics are comparable to many orally administered agents in clinical use and are consistent with the aim of designing prodrugs with clinical potential for oral administration.
In vitro studies
Provided cysteamine is not significantly released from the prodrugs during incubation in the medium, successful cellular uptake and hydrolysis of the prodrugs can be demonstrated by measuring the increased levels of intracellular cysteamine. The possibility of prodrug hydrolysis in fetal bovine serum-containing medium was investigated in separate experiments using prodrug 1a
and γ-glutamyl-cysteamine 4 with LC-MS analysis. Slow hydrolysis of the thioester and, to a lesser extent, the α-carboxyl ester was observed, but the γ-glutamyl-cysteamine bond was not cleaved over 24 hours (data not shown). It was concluded that hydrolysis of the prodrug to release cysteamine by the action of serum esterase and GGT in the culture medium was unlikely.
Exposure of cultured cells to the prodrugs, followed by measurement of the resulting intracellular cysteamine concentrations, allowed the investigation of three indicators: the uptake of prodrugs into the cells, the successful ester/thioester hydrolysis of the prodrugs, and the release of cysteamine from γ-glutamyl-cysteamine 4. Following treatment of cultured proximal tubule epithelial cells with test agents, the intracellular cysteamine concentration was quantified using 2-chloro-1-methylquinolinium tetrafluoroborate (CMQT) as a pre-column derivatising agent and HPLC. CMQT reacts instantaneously and highly specifically with thiols, under mild conditions, to form a thiol-CMQT derivative that can be quantified using HPLC with ultraviolet or fluorescent detection [34] . HPLC conditions, equipment and validation data are included in the Supporting Information.
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Prodrug uptake and cysteamine release in proximal tubular cells
A normal cultured human proximal tubular (kidney) cell line, PT37 [37] , was used to assess the cellular uptake and release of cysteamine from esterified prodrugs 1a-c, 2a and 3a, using cysteamine and its disulfide cystamine as controls. The concentration of 20 µM prodrug was chosen to mimic cysteamine levels in the blood of patients treated with Cystagon ® and is in line with the established EC 50 of 12.5 µM [7] . Following prodrug exposure, the intracellular concentration of cysteamine was measured after cell lysis, centrifugation and Bradford assay of the pellet protein content, supernatant thiol derivatization with the tagging agent CMQT, followed by HPLC analysis using simultaneous UV and fluorescence detection, Figure 2 . Analysis of untreated PT37 cells showed no cysteamine-CMQT peak, indicating an initial intracellular cysteamine concentration below the level of detection (< 160 nM). Cysteamine uptake into cells following treatment with cysteamine hydrochloride was confirmed by the detection of cysteamine-CMQT. Cysteamine uptake was rapid, peaking after two hours; the level was maintained at 0.84 ± 0.06 nmol/mg protein until around 6 hours, dropping to 0.22 ± 0.04 nmol/mg protein after 24 hours, suggesting that cysteamine is metabolized after internalization. The intracellular level of cysteamine did not continue to rise when its concentration was maintained in the medium at 20 µM, supporting the observation that cysteamine uptake may be saturable [38] .
When exposed to air, cysteamine is rapidly oxidized to its disulfide form, cystamine [39] , particularly when in dilute aqueous solution. The rate of oxidation of cysteamine hydrochloride in aqueous solution was investigated by HPLC with UV detection, using pre-analysis derivatisation by CMQT. Only the reduced thiol form can react with CMQT and is selectively detected, Figure 3 . The oxidation of cysteamine hydrochloride in water (pH 4.66) occurred rapidly, falling to 50% within 1 hour; after approximately 3 hours, there was no detectable cysteamine in the solution.
When PT37 cells were treated directly with the disulfide, cystamine dihydrochloride, the total intracellular levels of cysteamine were considerably lower than those observed when the same cells
14 were treated with cysteamine hydrochloride; the dicationic hydrophilic nature of cystamine is likely to hinder uptake into the cell and the efficiency of its intracellular bioreduction has not been established, thus cystamine has not found application for the treatment of cystinosis. In addition to extensive first pass metabolism, oxidation to the disulfide may be partly responsible for the poor bioavailability of cysteamine in the therapy of cystinosis. A number of thioesters of cysteamine were synthesized and showed significantly increased stability to oxidation compared to cysteamine (data not shown). The use of thioester groups in the prodrugs inhibits oxidation of the free thiol to the disulfide with the aim of increasing cysteamine bioavailability.
Cysteamine-CMQT was also observed when cells were treated with any of prodrugs 1a-c, 2a and 3a, providing evidence for their uptake and hydrolysis to release cysteamine. Peak levels of cysteamine were not reached until 6 hours after exposure, consistent with the requirement for enzymatic action on the α-carboxyl ester, thioester, and γ-glutamyl groups to release cysteamine. In agreement with the measured log P values (Table 2) , the S-acetyl prodrugs 1a-c (with lower MlogP values) were associated with a slower increase in cysteamine concentration than the S-benzoyl 2a
and S-pivaloyl 3a prodrugs (with higher MlogP values and greater lipophilicity). In this instance, due to the minimal hydrolysis of esters in the culture medium, it is probable that the ester/thioester prodrugs were internalised by passive diffusion, with no involvement of GGT, and broken down intracellularly to release cysteamine.
Conclusion
Nine esterified γ-glutamyl-cysteamine prodrugs were designed to overcome some of the undesirable properties of the pharmaceutical product cysteamine. Derivatization as the γ-glutamyl-derivative was successful, offering increased metabolic stability, and physicochemical properties suitable for oral bioavailability were achieved by esterification of the glutamate α-carboxyl group, while oxidation of the thiol was inhibited by thioester formation. In addition, particularly low cytotoxicity of 1a, 1b and 1c in HaCaT keratinocytes was observed using the MTT Eur. J. Med Chem. 109 (2016) 206-215.
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assay; α-ethyl esters 2a and 3a showed similar cytotoxicity to that of cysteamine in this system, while acetyl thioesters 1a-c exhibited lower cytotoxicity than cysteamine. These ester/thioester γ-glutamyl-cysteamine prodrugs displayed uptake into cells, ester and thioester hydrolysis, and release of cysteamine, with a delay to its release consistent with the requirement for activation of the prodrug. Furthermore, the prodrugs maintained the concentration of cysteamine at above baseline levels for at least 24 hours, comparative to or better than that achieved by cysteamine hydrochloride and significantly better than that achieved by cystamine dihydrochloride. These data support the in vivo efficacy evaluation of cysteamine prodrugs in a validated animal model for their potential as an alternative oral treatment for cystinosis.
This targeted prodrug approach to the delivery of cysteamine may also have application to the treatment of other diseases, such as Huntington's disease, cystic fibrosis and non-alcoholic steatohepatitis (NASH), in which recent research has demonstrated a beneficial effect of cysteamine.
Experimental
Supporting Information available: general methods and examples are shown in this section.
Full experimental data are available as Supporting Information.
The structures of products were assigned using IR, 1 H NMR and 13 C NMR spectroscopy, including 2D techniques (COSY, HMQC, HMBC), and by mass spectrometry. The purity of products was confirmed as >95 % using elemental analysis, HPLC with UV detection, or LC-MS.
Unless stated otherwise, all chemicals and solvents were obtained from Sigma Aldrich (UK) and used without further purification. Solvents were dried using the Pure Solv TM purification system (Innovative Technology, Inc). TLC was carried using silica gel matrix on aluminium foil (Sigma Aldrich). Column chromatography used silica gel, particle size 35-70 micron (Fisher Scientific).
CHN analysis, NMR spectroscopy and mass spectrometry were carried out using, respectively, an
Exeter Analytical CE 440 Elemental Analyzer instrument, AVANCE DPX 300MHz Bruker NMR instrument at 300 MHz ( 1 H) or 75MHz ( 13 C) and an Esquire 3000+ Ion Trap mass spectrometer. IR spectroscopy was carried out with a Perkin Elmer Spectrum BX FT-IR system. Melting point determination was carried out using a Stuart SMP 30 melting point apparatus. ESI HRMS was performed courtesy of the EPSRC National Mass Spectrometry Service Centre. 
General method for preparation of compounds
2-(S)-tert-Butoxycarbonylamino-pentanedioic acid 5-benzyl ester 1-propyl ester (6b)
Following the procedure described in 4.1, the reaction of 2-tert-butoxycarbonylamino- 
General method for preparation of compounds 7a-c
Compounds 6a-c were dissolved in methanol (50 mL). Palladium on carbon (10%, Alfa Aesar) was added (0.1 mass equivalent) and the mixture was stirred for approximately 3 hours, at room temperature, under a hydrogen atmosphere at 3 bars of pressure. The catalyst was removed by filtration over celite and the resulting solution was concentrated under reduced pressure to afford a colourless oil, which was dissolved in a minimum amount of ethyl acetate, and then hexane was added until the solution became turbid. The solution was stored at 0°C overnight and the resultant precipitate was collected by filtration.
2-(S)-tert-Butoxycarbonylamino-pentanedioic acid 1-butyl ester (7c)
Following the procedure described in 4. 
General method for preparation of compounds 8a-c
Compounds 7a-c were dissolved in dry DCM (1g in 50 mL) under nitrogen. To this was added triethylamine (1 mol equivalent), HOBt (1 mol equivalent) and 1,3-diisopropylcarbodiimide (1 mol equivalent)and the mixture was stirred, at 0⁰C for 15 minutes. Cysteamine hydrochloride (1 mol equivalent) was then added and the mixture stirred at 0°C for 45 minutes, then at room temperature overnight. The solution was filtered and the combined organic layers were washed with 10% w/v potassium carbonate, 10% w/v citric acid and water, and then dried over magnesium sulfate. The resulting solution was concentrated under reduced pressure to afford the crude product.
Purification by column chromatography (petrol/ethyl acetate as eluent) on silica was carried out to obtain the corresponding pure compound as a white solid 8a-c.
2-(S)-tert-Butoxycarbonylamino-4-(2-mercapto-ethylcarbamoyl)-butyric acid butyl ester (8c)
General method for preparation of compounds 9a-c
Compounds 8a-c and triethylamine (1 mol equivalent) were protected from moisture and stirred in dry THF (1g in 30 mL) at room temperature. To this acetic anhydride (1 mol equivalent) was added and the mixture stirred at 40⁰C overnight. The organic layer was washed with 10% potassium carbonate, brine and water, and then dried over magnesium sulfate. The resulting solution was concentrated under reduced pressure to afford the product crude product. Purification by column chromatography on silica (dichloromethane/methanol as eluent) on silica was required for obtaining the corresponding pure products 9a-c as a white solid.
4-(2-Acetylsulfanyl-ethylcarbamoyl)-2-(S)-tert-butoxycarbonylamino-butyric acid butyl ester (9c)
Following the procedure described in 4.4, the reaction of compound 8c (1.00 g, 2.76 mmol)) with acetic anhydride gave product 9c (0. 
General method for preparation of compounds 10a-c
Compounds 8a-c were stirred in dry dichloromethane (1g in 30 mL), under dry conditions and at room temperature. To this was added pyridine (1 mol equivalent) and benzoyl chloride (1 mol equivalent) and the mixture was stirred at room temperature overnight. The organic layer was washed with 10% potassium carbonate, brine and water, and then dried over magnesium sulfate.
The resulting solution was concentrated under reduced pressure to afford the crude product. Column chromatography (petrol/ethyl acetate as eluent) on silica was required to obtain the corresponding pure product 10a-c as a white solid.
4-(2-Acetylsulfanyl-ethylcarbamoyl)-2-(S)-tert-butoxycarbonylamino-butyric acid ethyl ester (10a)
Following the procedure described in 4.5, the reaction of compound 8a (0. 
General method for the preparation of compounds 11a-c
Compounds 8a-c were stirred in dry dichloromethane (1g in 30 mL), under dry conditions and at room temperature. To this was added pyridine (1 mol equivalent) and pivaloyl chloride (1 mol equivalent) and the mixture was stirred at room temperature overnight. The organic layer was washed with 10% potassium carbonate, brine and water, then dried over magnesium sulfate. The resulting solution was concentrated under reduced pressure to afford the crude product. Column chromatography (petrol/ethyl acetate as eluent) on silica and recrystallisation (ethyl acetate/hexane) was required to obtain the corresponding pure product 11a-c as a white solid.
2-(S)-tert-Butoxycarbonylamino-4-[2-(2,2-dimethyl-propionylsulfanyl)-ethylcarbamoyl]-butyric acid propyl ester (11b)
Following the procedure described in 4.6, the reaction of compound 8b (0.20 g, 0.57 mmol) with pivaloyl chloride gave product 11b (0. 
Cell lines
HaCaT keratinocytes were commercially obtained from Cell Line Services. PT37 cells were donated by the Leuven University Hospital, Belgium. Cell lines were cultured in DMEM/F12 medium (Invitrogen) supplemented with 2 mM L-glutamine (1%, Sigma Aldrich), penicillinstreptomycin (1%, Sigma Aldrich) and heat inactivated fetal calf serum (10%, Biosera). Cell monolayers were maintained at 37 °C under an atmosphere containing 5% carbon dioxide.
General method for MTT assay
Prodrugs were dissolved in medium to give a starting concentration of 500 g/mL. In a 96
well plate, serial dilutions were carried out to give subsequent concentrations of 250, 125, 62.5, 
General method for Sirius T3 measurement of pK a and Log P
To measure the pK a , between 1-2 mg of test compound was weighed accurately into a vessel and placed into the Sirius T3 instrument for pH metric analysis. The pK a was computationally determined following the automated potentiometric acid-base titration over a pH range of 2 to 12 (mean of 3 titrations). For the automated pH-metric measurement of Log P, an accurately weighed sample was dissolved in a two-phase water-octanol system (1:2), and titrated over a pH range (2 to 12). Log P results were obtained by computational process using the Sirius T3 software.
General method for measurement of total cellular cysteamine content
Test prodrugs were dissolved in culture medium to obtain the required concentration (20 µM). Confluent cell monolayers were incubated with the prodrug-containing medium at 37°C for a defined time period (0, 2, 6, 16 or 24 hours). Monolayers were harvested using trypsin-EDTA (0.25%), re-suspended in growth medium and centrifuged for 5 minutes at 1000 rpm. The resulting cell pellets were washed with cold PBS with centrifugation at 1000 rpm for a further five minutes.
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The pellets were then re-suspended in sucrose (400 µL, 0.25 M) and sonicated before the suspension was centrifuged at 13,000 rpm for ten minutes. Following pellet suspension, 10 µL of the cell supernatant was added to a microplate (in triplicate). To this, was added 240 µL Bradford reagent (Sigma Aldrich, Poole, UK) and the plate incubated for 5 minutes at 37 °C. The absorbance was then measured at 595 nm. The protein concentration was determined by comparison to a calibration curve prepared using bovine serum albumin standards (0.1 -1.5 mg/mL protein).
The 
